Drugs / Complarate®
Complarate®
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06488521 | Jun 2024 → Apr 2025 overdue | — | AO GENERIUM | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06481202 | Apr → Jun 2022 | — | AO GENERIUM | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06475508 | Feb 2023 → Jan 2024 | rheumatoid arthritis | AO GENERIUM | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07709000 Background | Aug 2026 → Nov 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Complarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481202 ↗ |
| Known as | tocilizumab | “Complarate (tocilizumab) is being developed as a biosimilar to the drug Actemra®, a concentrate for the preparation of a solution for infusion.” NCT06481202 ↗1“Complarate (tocilizumab, solution) is being developed as a biosimilar to the drug Actemra®, a solution for subcutaneous injection.” NCT06488521 ↗ |
| Known as | Tocilizumab biosimilar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709000 ↗ |
| Route | Intravenous | “The investigational drug Complarate® was administered as an intravenous infusion” NCT06475508 ↗ |